SCHEMBL5650677

SCHEMBL5650677

O=C(Oc1ccc(Oc2ccc(C(F)(F)F)cc2)cc1)N1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 7/20 0.73
BCHE P06276 1/20 0.73
ALDH1A1 P00352 1/20 0.68
POLB P06746 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.67
MAPT P10636 2/20 0.67
HTT P42858 2/20 0.67
NPC1 O15118 2/20 0.67
RAB9A P51151 1/20 0.67
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
LMNA P02545 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
TRPV1 Q8NER1 1/20 0.53
TRPA1 O75762 1/20 0.52
SRD5A1 P18405 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277143 0.95 ALDH1A1 (0.74) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL21616684 0.94 ALDH1A1 (0.71) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL5652083 0.86 LIPE (0.74) LIPEBCHESMN1; SMN2NPC1RAB9A
SCHEMBL5649451 0.85 LIPE (0.58) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL5646210 0.85 LIPE (1.00) LIPEBCHESMN1; SMN2MAPTHTT
SCHEMBL5647711 0.85 LIPE (0.58) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL5650334 0.82 LIPE (0.53) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL5653225 0.81 ALDH1A1 (0.77) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL8845496 0.81 ALDH1A1 (0.77) LIPEBCHEALDH1A1POLBSMN1; SMN2
SCHEMBL31717900 0.80 SMN1; SMN2 (0.82) LIPEBCHEALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL LIPE 1/4885BCHE 126/4885ALDH1A1 1304/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL LIPE 1/4885BCHE 112/4885ALDH1A1 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.